CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74,2% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär BioNTech BNTX

BioNTech realtidsdiagram

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Senaste nyheter

Frances Wang 2025 Mar 31, 16:00

Gold Prices Hit New Highs: What is Gold CFD trading?

Commodities
Frances Wang 2025 Mar 31, 16:00

Oil Markets Today: Oil Falls on OPEC+ Output Hike and Trump’s Tariffs

Commodities
Tommy Yap 2025 Mar 29, 16:00

Week Ahead: U.S. Non-Farm Payrolls Coming Up: What to Expect

Forex Indices
Frances Wang 2025 Mar 27, 16:00

Stock market today: S&P 500, Dow, Nasdaq slip on Trump's tariff escalation

Indices
Frances Wang 2025 Mar 27, 16:00

Forex news today: EUR/USD Struggles to Gain Traction Amid Tariff Threats

Forex
Tommy Yap 2025 Mar 27, 16:00

Morning Note: U.K. Retail Sales, U.S. Core PCE & Canada GDP Outlook

Morning Note Forex
Tommy Yap 2025 Mar 26, 16:00

Morning Note: U.S. GDP, Canada Inflation & SEC Crypto-Friendly Plans

Morning Note USD CAD Cryptocurrencies
Frances Wang 2025 Mar 25, 16:00

Central Banks Weigh Interest Rate Moves Amid Inflation Debate

Fed

Info

Spread

1.1479

Spread (%)

1.2887 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaden är öppen

Tisdag

13:31 - 19:59

Måndag

13:31-19:59

Onsdag

13:31-19:59

Torsdag

13:31-19:59

Fredag

13:31-19:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

22785214464

Utelöpande aktier

239971008

Rapportdatum (nästa)

0000-00-00

Utd-procent

2022-06-17

Datum efter utdelning

2022-06-02

Förväntad framtida årlig utdelningsprocent

0

Förväntad framtida årlig direktavkastning

0

Vinst per aktie

-3.01

Läs mer om detta instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)
Relaterade instrument
Trustpilot